Wockhardt has build strong presence in the Indian market with focused efforts on high growth chronic therapeutic segment. Wockhardt has a 1,500-strong field force covering over 2,00,000 medical practitioners. The Company's strong focus covers 50% of the therapeutic segments through six therapy-focussed marketing divisions. Wockhardt's has a significant presence in pain management, cough therapy, psychotic drugs, diabetology, vaccines, nutrition and animal health. Our focus on Power Brands has helped push the growth further, with some of our brands having strong leadership profiles.

Some of  Wockhardt's Power Brands include:

	Diabetology Wosulin (Recombinant Insulin) Mopaday (Oral Antidiabetic) Glimaday (Oral Antidiabetic) Nephrology Wepox (Recombinant Erythropoietin)
	Pain Management Proxyvon Spasmo-Proxyvon Nutrition Methycobal Dexolac Decdan
	Neuro-Psychiatry Libotryp Tryptomer Cough Therapy Zedex Bro-Zedex Viscodyne

The Company enjoys excellent brand and customer equity, which has given it leadership positions in its chosen areas of focus.

Wockhardt’s forte in the Indian market has made it the partner of choice for reputed international companies. Today, Methycobal, which is licensed from Eisai, Japan, is the largest selling brand in the segment and features amongst the Top 50 brands in the country.

Wockhardt offers the requisite resources, distribution & marketing infrastructure, and brand equity in the Indian market to make it the ideal partner.

Partnerships for the Indian market